Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 1
1978 2
1979 1
1981 4
1982 4
1983 4
1984 2
1985 2
1986 1
1987 1
1988 2
1989 5
1990 7
1991 9
1992 11
1993 10
1994 11
1995 17
1996 20
1997 16
1998 6
1999 6
2000 5
2001 4
2002 8
2003 7
2004 6
2005 10
2006 24
2007 19
2008 20
2009 12
2010 13
2011 10
2012 18
2013 19
2014 20
2015 20
2016 26
2017 16
2018 27
2019 21
2020 24
2021 28
2022 40
2023 49
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

579 results

Results by year

Filters applied: . Clear all
Page 1
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV; HORIZON (OP-106) Investigators. Richardson PG, et al. Among authors: mazumder a. J Clin Oncol. 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. Epub 2020 Dec 9. J Clin Oncol. 2021. PMID: 33296242 Free PMC article. Clinical Trial.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Lonial S, et al. Among authors: mazumder a. Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7. Lancet. 2016. PMID: 26778538 Clinical Trial.
Dermatologic needs of Afghan refugees.
Mazumder A, Mehrmal S, Chaudhry SB. Mazumder A, et al. JAAD Int. 2022 Aug 18;9:72-74. doi: 10.1016/j.jdin.2022.08.002. eCollection 2022 Dec. JAAD Int. 2022. PMID: 36147216 Free PMC article. No abstract available.
A new twist on PIFE: photoisomerisation-related fluorescence enhancement.
Ploetz E, Ambrose B, Barth A, Börner R, Erichson F, Kapanidis AN, Kim HD, Levitus M, Lohman TM, Mazumder A, Rueda DS, Steffen FD, Cordes T, Magennis SW, Lerner E. Ploetz E, et al. Among authors: mazumder a. Methods Appl Fluoresc. 2023 Oct 12;12(1):012001. doi: 10.1088/2050-6120/acfb58. Methods Appl Fluoresc. 2023. PMID: 37726007 Free PMC article. Review.
Sinigrin and Its Therapeutic Benefits.
Mazumder A, Dwivedi A, du Plessis J. Mazumder A, et al. Molecules. 2016 Mar 29;21(4):416. doi: 10.3390/molecules21040416. Molecules. 2016. PMID: 27043505 Free PMC article. Review.
Streptomyces: The biofactory of secondary metabolites.
Alam K, Mazumder A, Sikdar S, Zhao YM, Hao J, Song C, Wang Y, Sarkar R, Islam S, Zhang Y, Li A. Alam K, et al. Among authors: mazumder a. Front Microbiol. 2022 Sep 29;13:968053. doi: 10.3389/fmicb.2022.968053. eCollection 2022. Front Microbiol. 2022. PMID: 36246257 Free PMC article. Review.
The medicinal chemistry of piperazines: A review.
Faizan M, Kumar R, Mazumder A, Salahuddin, Kukreti N, Kumar A, Chaitanya MVNL. Faizan M, et al. Among authors: mazumder a. Chem Biol Drug Des. 2024 Jun;103(6):e14537. doi: 10.1111/cbdd.14537. Chem Biol Drug Des. 2024. PMID: 38888058 Review.
579 results